Core Insights - Vitarion is a clinical-stage biotechnology company focused on developing transformative therapies for neurodegenerative diseases, inflammatory and immune diseases, metabolic disorders, and rare diseases [2] Group 1: Company Overview - Vitarion was established in 2017 and has developed a diversified project pipeline targeting key drivers of aging, degenerative changes, metabolic dysfunction, and inflammation [2] - The company is currently conducting clinical studies on NAMPT activator SIR4156, SARM1 inhibitor SIR2501, and RIPK1 inhibitor SIR9900, while also advancing preclinical research [2] - Vitarion was recognized in the 2025 Endpoints 11 list of most promising biotechnology startups [2] Group 2: Upcoming Conference - Vitarion will present a scientific poster titled "Targeting NAMPT Activation for the Treatment of Neuromuscular and Mitochondrial Diseases" at the NAD and Health: Opportunities and Challenges 2026 international conference in Copenhagen from March 23 to 25, 2026 [1] - The conference will explore whether regulating nicotinamide adenine dinucleotide (NAD⁺) metabolism can extend human healthspan and prevent or modulate age-related diseases [1] - The event aims to establish a framework for translating key findings from basic scientific research into therapies for neurodegenerative diseases, endocrine disorders, and cardiovascular metabolic diseases [1]